Absorption of magnesium from orally administered magnesium sulfate in man.
The use of magnesium sulfate (Epsom salt) as a cathartic in patients with impaired renal function can lead to severe toxicity due to hypermagnesemia. Although toxicity is uncommon in healthy subjects, little is known concerning the extent of absorption of magnesium after a cathartic dose of magnesium sulfate. The bioavailability of magnesium following a large oral dose of magnesium sulfate in normal volunteers was examined in the present investigation. Baseline 24-hour urinary excretion rates of magnesium and creatinine were determined over 3 consecutive days in 6 healthy men. The oral administration of 13.9 g (56.5 mmoles) magnesium sulfate U.S.P., in 4 equal hourly increments, resulted in the urinary excretion (corrected for baseline excretion rate) of 4.0 +/- 2.9% (mean +/- SD) of the dose of magnesium during the first 24 hours and 6.9 +/- 7.0% of the dose during a 72-hour interval. Magnesium sulfate administration had no effect on the 24-hour urinary excretion rate of creatinine. The baseline excretion rate of magnesium was significantly correlated with that of creatinine (r = 0.875) and inorganic sulfate (r = 0.921). All of the subjects experienced mild or moderate diarrhea. Therefore, magnesium is absorbed to a limited and variable extent in healthy adults following a cathartic dose of magnesium sulfate.
Department of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo, Amherst 14260.
M E
ME
Morris
S
S
LeRoy
S C
SC
Sutton
D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D003404:Creatinine / Q000032:analysis; D003967:Diarrhea / Q000139:chemically induced; D006801:Humans; D007408:Intestinal Absorption; D008278:Magnesium Sulfate / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000652:urine; D008297:Male
D008278:Magnesium Sulfate; D003404:Creatinine